As a result, PPA1-DOX conjugate was found to exhibit a significantly lower toxicity to non-tumor cells, in particular for cardiomyocytes and hepatocytes that are major toxic targets of DOX (28, 29), and a remarkably higher antitumor activity in vivo, as compared with DOX and free PPA1, respectively. Here, PPA1 is linked to neoplasm.